Viemed Healthcare, Inc. (VMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong financial performance with 24% revenue growth and a 22.4% EBITDA margin. Positive factors include raised guidance, successful acquisitions, and increased share repurchases. Concerns about competitive bidding and unclear management responses in the Q&A may temper enthusiasm slightly, but overall sentiment remains positive due to growth and strategic initiatives.
Key Financial Performance
Revenue $71.9 million, representing 24% growth year-over-year and 14% sequential growth from the second quarter. The growth reflects solid organic growth and the immediate accretion from the Lehan's acquisition.
Gross Profit $41.3 million or a 57.5% gross margin. This reflects strong operational performance and diversification.
Adjusted EBITDA $16.1 million, up 16% from the prior year, representing a 22.4% margin. This is attributed to continued investments in growth and diversification.
Net Income $3.5 million or $0.09 per diluted share. This reflects the company's profitability amidst growth investments.
PAP Therapy Patients Increased 64% year-over-year and 21% sequentially in the third quarter. This growth is driven by strong organic execution and the integration of Lehan's acquisition.
SG&A Expenses 44.4% of revenue, a 160 basis point improvement compared to last year and a 130 basis point improvement sequentially. This improvement is due to the evolving product mix and disciplined cost management.
Gross Capital Expenditures $7.6 million in the quarter, down from $11 million a year ago. This decrease is due to normalized spending following the completion of the Philips Vent Exchange program.
Trailing 12-Month Free Cash Flow $23.3 million, up significantly from the prior year. This reflects strong cash flow generation and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ventilation Revenue: Achieved double-digit year-over-year growth, reflecting sustained demand for the clinical model.
Sleep Growth: New sleep patient starts grew 96% year-over-year, and resupply population increased 51% year-over-year and 33% sequentially.
Maternal Health: Successfully integrated Lehan's Medical Equipment, built first maternity claims outside the acquired network, and made progress toward a national rollout.
Geographic Expansion: Expanded sleep footprint into new markets through the addition of 2,465 patients from Lehan's acquisition.
Diversified Revenue Streams: Core ventilation business now accounts for less than half of net revenue, reflecting diversification into new service lines.
AI-Powered Revenue Cycle Management: Deployed tools in the sleep business, improving efficiency, accuracy, and scalability in billing and collections.
Operational Efficiencies: SG&A expenses reduced to 44.4% of revenue, reflecting improved cost management and evolving product mix.
Acquisition of Lehan's Medical Equipment: Integrated the acquisition, which diversified the portfolio and contributed to immediate accretion.
Share Repurchase Program: Completed the 2025 program, repurchasing nearly 2 million shares at an average price of $6.69.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes: The implementation of new national coverage determination requirements for at-home ventilation could pose challenges in ensuring readiness and compliance. While the company is preparing for these changes, the impacts are expected to materialize in the coming months, potentially affecting operations and payment flows.
Market Diversification: The shift in revenue streams, with the core ventilation business now accounting for less than half of net revenue, indicates a reliance on newer service lines. This diversification, while beneficial, could introduce risks if new services fail to perform as expected or face market resistance.
Integration of Acquisitions: The integration of Lehan's Medical Equipment, while progressing well, requires alignment of systems, processes, and culture. Any misalignment could disrupt operations or impact service quality.
Economic Uncertainties: Economic conditions could impact the company's ability to sustain growth, particularly in newer service lines like maternal health and sleep services, which are still scaling.
Operational Costs: While SG&A expenses have improved as a percentage of revenue, the company continues to invest heavily in growth and diversification. This could strain financials if expected returns are not realized.
Competitive Pressures: The healthcare sector is highly competitive, and the company’s ability to maintain its leadership in home-based healthcare could be challenged by competitors offering similar or superior services.
Supply Chain and Staffing: The company’s Healthcare Staffing division is performing well, but any disruptions in staffing or supply chain could impact its ability to deliver consistent patient care.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Net revenue for the full year is expected to be between $271 million and $273 million, reflecting a narrowed range for better visibility. Adjusted EBITDA is projected to be between $60 million and $62 million, representing approximately 22% of revenue.
Regulatory Changes: The company is preparing for the implementation of new national coverage determination requirements for at-home ventilation, which took effect in June. These changes are expected to improve payment flows through Medicare Advantage channels and streamline approvals.
Sleep Business Growth: The sleep business is experiencing accelerated growth, with new sleep patient starts growing 96% year-over-year and the resupply population increasing 51% year-over-year. This segment is expected to continue as a key driver of diversified growth.
Maternal Health Expansion: Maternal health services, integrated through the Lehan's acquisition, are poised to become a significant growth driver in 2026, with progress toward a national rollout.
AI-Powered Revenue Cycle Management: AI tools are being deployed to improve efficiency, accuracy, and scalability in billing and collections, initially targeting the sleep business and planned for expansion across other service lines in 2026.
Capital Allocation and Acquisitions: The company remains focused on investing in profitable growth, pursuing strategic acquisitions, and returning capital to shareholders. The balance sheet is strong, with $11.1 million in cash and $38 million available on credit facilities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: In September, the company completed the share repurchase program authorized by the Board. This marks the third buyback program since becoming public. Nearly 2 million shares were repurchased at an average price of approximately $6.69.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Excluding the contribution from Lehan's, what was the organic growth percentage?
A:The organic growth percentage was around 14%.
Q:What factors contributed to the growth in the sleep segment?
A:The growth in the sleep segment was attributed to gaining market share, hiring reps specifically for selling sleep, leveraging breast pump sales, and training reps effectively. The company also focused on infrastructure and insurance contracts before launching sleep products nationwide.
Q:What are the company's views on the return of competitive bidding?
A:The company anticipates the return of competitive bidding and believes operationally sound and larger companies will win more contracts. They plan to participate in virtually all CBAs and are monitoring the program's design. The maternal side of the business is insulated from competitive bidding as it is heavily commercial and Medicaid-based.
Q:What is the company's response to the stock underperformance despite good KPIs?
A:The company believes a multiple reset will occur due to their strong free cash flow generation. They are monitoring capital allocation aggressively, focusing on paying off debt, acquisitions, and potential stock buybacks.
Q:What changes were observed in the payer mix this quarter, and how does it impact the company?
A:The payer mix shifted with lower Medicare exposure due to product diversification and the Lehan's acquisition, which has minimal Medicare revenue. Medicare remains a great payer with timely payments and manageable audits. The company's AR is low, indicating efficient revenue cycle management.
Q:What operational levers can the company pull to protect mix and margin as sleep and resupply grow?
A:The company is using technology initiatives, such as AI-based intake, to streamline processes and improve compliance. They are also focusing on SG&A improvements to offset gross margin pressures from the growth in sleep and resupply.
Q:What are the company's growth focus areas geographically?
A:The company focuses on expanding in rural markets close to existing reps, particularly in the Deep South and COPD-prevalent areas like Kentucky, Tennessee, and West Virginia. They are also planning a nationwide approach for maternity products.
Q:Why has revenue per patient in the sleep therapy segment been declining?
A:The decline is due to the shift in revenue mix, with resupply overtaking therapy patients. Resupply has a different revenue profile, with stable realizations of approximately $200 per order and 50% gross margin.
Q:What are the company's priority areas for technological advancements?
A:The company is prioritizing investments in AI and machine learning, particularly in the intake division to streamline manual processes. They are exploring additional areas for AI implementation to improve scalability, efficiency, and operational performance.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about what it would take to get investor interest and turn the sector around. They acknowledged the difficulty of the question and emphasized their strong free cash flow and capital allocation strategies but did not provide a clear or specific solution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Lehan Medical
Medical Equipment
Medicare Advantage
ability
access
acquisition
adaptability
addition
care patient
change
collaboration
colleague
commitment
coverage
culture
dedication
division
driver
excellence
experience
footprint
foundation
milestone
model
patient care
patient partner
patient start
portfolio
priority
quality
service expansion
service line
service offering
sleep
staff
success
team
teamwork
term value
tool
ventilation
vision
VMD Transcript
Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript
Positive5-6
The company demonstrates strong financial performance with a 28% revenue increase and improved free cash flow. Despite regulatory challenges, the guidance is optimistic, supported by strategic growth in sleep and maternal health sectors. The share repurchase program signals confidence in long-term value. Positive sentiment is further reinforced by analysts' acknowledgment of potential upside in guidance. However, near-term pressures from NCD criteria and seasonal revenue patterns temper enthusiasm, resulting in a positive, yet moderate, stock price outlook.
Savaria Corporation (SIS:CA) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary indicates strong financial performance, with significant increases in revenue, net earnings, and EPS. The Q&A session reveals some uncertainties, but management's optimism about margin expansion and strategic acquisitions suggests positive sentiment. The combination of strong financial metrics, optimistic future guidance, and strategic growth plans supports a positive stock price outlook.
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
Positive3-5
The company reported strong financial results with record revenue growth, especially in the sleep and maternal health segments, and maintained stable margins. The strategic focus on expanding the Lehan acquisition and efficient capital allocation is promising. Despite some concerns about RTs and margin stability, the positive growth outlook and shareholder returns suggest a positive stock movement. The lack of market cap information limits precise impact prediction, but overall sentiment leans positive.
Viemed Healthcare, Inc. (VMD) Q3 2025 Earnings Call Transcript
Positive11-7
The company reported strong financial performance with 24% revenue growth and a 22.4% EBITDA margin. Positive factors include raised guidance, successful acquisitions, and increased share repurchases. Concerns about competitive bidding and unclear management responses in the Q&A may temper enthusiasm slightly, but overall sentiment remains positive due to growth and strategic initiatives.
VMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
